HCPLive Network

Phase III Study Results for Levomilnacipran Promising

Forest Laboratories and Pierre Fabre Medicament made an announcement today stating that the main goal of their phase three study for levomilnacipran, a possible future treatment of major depressive disorder (MDD), had been achieved.

These recent findings are a relief for the two developmental partners as well as the medical community, especially since a previous phase three study earlier this year of levomilnacipran failed to exhibit optimistic results; the findings of that study showed that the drug decreased depression no more effectively than a placebo.

The purpose of this double-blind, randomized, placebo-controlled study was to test the drug's efficacy, safety, and tolerability.

The eight-week trial focused on 720 patients, whose depression was measured by the six-point Montgomery-Asberg Depression Rating Scale (MADRS). The researchers found that levomilnacipran decreased the depression of the participants, and further, they discovered that the participant’s scores lowered as doses increased.

MDD is estimated to affect roughly fifteen-million people in the United States each year.

"Depressed patients often struggle to find the right antidepressant and the need for new medications is high," said Dr. Marco Taglietti, Forest president and senior vice president of research and development.

The drug works through inhibiting the re-uptake of norepinephrine and serotonin, which increases the levels of these two neurotransmitters that are known to affect mood.

"These positive Phase III results are very encouraging and support the continued research of levomilnacipran in adult patients with major depressive disorder," concluded Taglietti.
 
Further Reading
A perioperative dose of pregabalin can reduce pain after an oculoplastic eyelid procedure, according to the results of a small study.
The cannabis-based multiple sclerosis drug Sativex has been recommended for use in Wales, making it the first in the United Kingdom to do so. The drug awaits final approval from the government.
Eliquis is also now indicated for reducing the risk of recurrent DVT and PE following initial therapy.
Greater physical activity is associated with lower rates of incident atrial fibrillation in women, according to a study published online Aug. 20 in the Journal of the American Heart Association.
The association between obesity and subsequent dementia varies with the age at which obesity is first recorded, according to a study published online Aug. 20 in the Postgraduate Medical Journal.
High-mitotic-rate primary cutaneous melanomas more often occur on the head and neck and in men, older patients, and those with a history of solar keratosis, according to a study published online Aug. 20 in JAMA Dermatology.
A new agent tested in nonhuman primates shows efficacy in the treatment of the Marburg virus, a filovirus which is closely related to the Ebola virus, even in the late stages of the infection, according to research published in the Aug. 20 issue of Science Translational Medicine.
More Reading